Raia Drogasil S A : Comunicado ao Mercado

INSTITUTIONAL PRESENTATION

2Q22

Disclaimer

The material that follows is a presentation of general background information about RaiaDrogasil S.A. (the "Company") as of the date of the presentation. It is information in summary form and does not purport to be complete. It is not intended to be relied upon as advice to potential investors. This presentation is strictly confidential and may not be disclosed to any other person. No representation or warranty, express or implied, is made concerning, and no reliance should be placed on, the accuracy, fairness, or completeness of the information presented herein.

This presentation contains statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Exchange Act of 1934. Such forward-looking statements are only predictions and are not guarantees of future performance. Investors are cautioned that any such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and factors relating to the operations and business environments of the Company that may cause the actual results of the companies to be materially different from any future results expressed or implied in such forward-looking statements.

Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonable based on information currently available to the Company's management, the Company cannot guarantee future results or events. The Company expressly disclaims a duty to update any of the forward looking-statements.

Our securities have not been and will not be registered under the Securities Act or under any state securities laws in the United States, and are being offered under exemptions from registration under the Securities Act. Securities may not be offered or sold in the United States unless they are registered or exempt from registration under the Securities Act. Any offering to be made in the United States will be made by means of an offering circular that may be obtained from the agents.

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

2

Leading the consolidation of pharma retailing in Brazil.

Our Purpose:	+200 years
of combined history of Raia and
	Drogasil, merged in 2011

#1 Pharmacy

chain in Brazil

Taking close care of people's health and well-being during all times of their lives

2,581

pharmacies across every Brazilian state

45 million

unique active customers (2Q22 LTM)

307 million

tickets (2Q22 LTM)

R$ 28.0 billion

Gross revenue (2Q22 LTM, R$) +19% Y/Y growth

R$ 2.0 billion

EBITDA (2Q22 LTM) +15% Y/Y growth

260

new pharmacies in 2022 and 980 until 2025 (guidance)

NPS 90

net promoter score

500 million

digital sessions (annualized)

14.4%

market share in the 2Q22

AAA(bra)

rating by Fitch

3

Fragmented market with secular demand growth due to the ageing of the population.

Faster population ageing

(# of years for the population over 65 to grow from 7% to 14%. Source: The World Bank.)

Brazil (2011 - 2032)		21
China (2000 - 2026)	26
Japan (1970 - 1996)	26
Spain (1947 - 1992)	45
UK (1930 - 1975)	45
Canada (1944	- 2009)	65
USA (1944	- 2013)	69
Australia (1938 -2011)	73
Sweden (1890	- 1975)	85
France (1865	- 1980)	115

Pharmaceutical market should maintain

accelerated growth in the long term

(R$ billions. Source: IQVIA.)

144

126

																85	96 103113
											43	50	58	66	75
11	12	13	15	17	19	21	21	25	30	36
2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021

Population over 65 years

(Millions. Source: IBGE.)

				40.1
			30.0
		20.0
9.7	13.3
2000	2010	2020	2030	2040

Fragmented market: opportunity for consolidation

(Market share. Source: IQVIA.)

9.2%	9.8%	10.8%	11.4%	11.8%	13.4%	13.5%	14.1%
18.6%	17.5%	16.3%	16.4%	16.3%	16.0%	15.2%	15.2%
22.5%	24.7%	24.9%	23.9%	23.3%	22.3%	21.8%	21.0%
17.2%	15.9%	16.7%	17.6%	18.4%	19.1%	20.2%	22.0%
32.5%	32.1%	31.3%	30.7%	30.3%	29.1%	29.2%	27.6%
2014		2015	2016	2017	2018	2019	2020	2021
			Independents			Assoc./Franch.		Other Chains		Abrafarma #2 to 5		RD

4

RD completed 10 years of history, with strong growth and value creation based on a traditional retail strategy.

776 864

Pharmacies

(Store count)

3x

2,490

2,299

2,070

1,822

1,607

1,417

1,232

1,091

967

Employees

(Thousands)

3x

50.6

44.6

41.5

36.5

32.3

28.9

26.5

23.7

20.121.5

17.2

4.7 5.6

Gross revenue

(R$ billions)

5x

25.6

21.2

18.4

15.5

13.9

11.8

9.4

7.8

6.5

Adjusted EBITDA

(R$ millions)

7x

1,807

1,429

1,344

1,195

1,130

988

744

544

326 357

272

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

5